UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

A first-in-human study, the CALM trial, is evaluating the safety and efficacy of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. UCART, readily available for clinical use, is an allogeneic genome-edited anti-CD19 CAR T-cell product derived from healthy donors. A manageable safety profile was found, and the overall response rate after median follow-up of 12.8 months was 48% (95% CI: 28, 69).